Cardiac Manifestation of COVID-19 Patients and Their Outcome

Pallavi Yelne a≡, Shilpa Gaidhane a*, Chetan Rathi a#, Abhijit Wadekar a† and Shubham Nimkar a†

a Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha, Maharashtra, India.

Authors’ contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i61A35486

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/80838

Received 14 November 2021
Accepted 27 December 2021
Published 28 December 2021

ABSTRACT

COVID-19, the novel corona virus disease of 2019 pandemic caused by the SARS-CoV-2 virus has imminently threatened all of us having significant morbidity and mortality all around the world. Upper respiratory tract infection, pneumonia, severe acute respiratory distress syndrome, multiorgan failure or even death can be the manifestation of COVID-19. However, ‘n’ number of cardiac complications including acute myocardial injury, myocarditis, arrhythmia, pericarditis, decompensated heart failure and cardiogenic shock has been described so far. We report the first systematic and comprehensive echocardiographic evaluation of patients requiring hospitalization for COVID-19 infection. It was found that 32% of patients with COVID-19 have normal echocardiography. Out of all unavoidable cardiac complications in covid-19, due to pulmonary parenchymal and vascular disease, Right Ventricular (RV) dilation with or without dysfunction is the most frequent abnormality in patients who earlier had normal heart function. So, one of predictor of mortality in COVID-19 patients might be a RV function evaluation. The right ventricle dysfunction is at high risk in COVID-19 patients just because of its pathophysiological relevance. RV dysfunction is potentially resulting due to cytokines with its negative inotropic effects, directly angiotensin converting enzyme 2-mediated cardiac injury, acute respiratory distress syndrome and pulmonary

≡Assistant Professor;
*Professor and Unit Head;
#Cardiologist;
†Residents;
*Corresponding author: E-mail: drshilpagaidhane@gmail.com;
emboilm. They all are increasing preload and provoking RV failure. So, decrease in mortality and improvement in patient outcomes in COVID-19 patients can be achieved by early detection and management of right ventricle dysfunction. There is lack of data from the central India, so the study is being conducted.

Keywords: COVID-19; RV dysfunction; 2D ECHO; acute respiratory distress syndrome; pulmonary embolism.

1. INTRODUCTION

(COVID-19), The novel corona virus disease 2019, has threatened us from self-limiting mild upper respiratory tract infection to severe lower respiratory tract infection [pneumonia, acute respiratory distress syndrome (ARDS)], multiorgan dysfunction may leading to death [1,2] causing mortality and residual morbidity all over the world. Unavoidable cardiac complications and acute respiratory distress syndrome are fatal enough to cause high death rate. According to recent reports [1,3] cardiac complications has increased mortality and has high prevalence in COVID-19 [3].

However, laboratory parameters (troponin I) and only clinical assessment were utilised to calculate mortality and morbidity without any cardiac image based studies. In fact, patients with myocardial injury have markedly high mortality than normal individuals (59.6% vs. 8.9) in COVID 19. Cardiac arrhythmias, ischemia, decompensated heart failure and cardiogenic shock are the various cardiac disease presentation of infection in COVID-19 [4,5].

Heart failure and its multiple causes being best diagnosed with the help of transthoracic 2D echocardiography (2D ECHO) which supports patient, hospitalized in intensive care units for risk assessment, hemodynamic evaluation and it’s management. We will be conducting a transthoracic 2D ECHO examination of Patients with HRCT thorax (CT index 9 and more) highly suggestive of covid-19 infection.

Frequency of cardiac abnormalities will be assessed. Whether a provoked viral infection directly or indirectly by stress or cytokine induced myocardial dysfunction causing all cardiac complications or not, still unknown. Interestingly, in a recent study COVID-19 patients had Right Ventricular (RV) dilation with diminished function associated with elevated pulmonary arterial systolic pressure who earlier had normal heart function. So, one of the significant indicator of mortality in COVID-19 patients might be a RV function evaluation [6].

Picture 1. Mechanisms of RV dysfunction in COVID-19

The right ventricle dysfunction is at high risk in COVID-19 patients just because of its pathophysiological relevance. Pathophysiological relationship of RV with pulmonary vasculature leading to RV dysfunction and failure plays an important role in the sudden onset hemodynamic deterioration or arrhythmias or even a sudden cardiac death in patients with COVID-19 [7]. RV dysfunction is potentially resulting due to cytokines with its negative inotropic effects, directly angiotensin converting enzyme 2-mediated cardiac injury, ARDS and pulmonary embolism. They all increasing preload and provoke RV failure. So, to decrease in mortality and improvement in patient outcomes in COVID-19 patients can be achieved by early detection and management of right ventricle dysfunction. There is lack of data from the central India, so the study is being conducted.

2. AIM AND OBJECTIVES

2.1 Aim
- To study cardiac manifestations of COVID-19 patients and its outcome.

2.2 Objectives
- To perform a transthoracic 2D echocardiographic (2D-ECHO) evaluation of moderate to severe patients COVID-19 infection (HRCT Score of 9 and more) requiring hospitalization.
- To assess the frequency of cardiac abnormalities.
- To examine the echocardiographic parameters and clinical condition (NEWS 2).
- To correlate clinical outcome during their hospitalization with echocardiographic assessment.

2.3 Research Question
- Are Cardiac Manifestations very common in COVID-19 patients?

2.4 Null Hypothesis
- Cardiac functions are normal in COVID-19 patients.

2.5 Alternate Hypothesis
- Cardiac Manifestations are common in COVID-19 patients.

“PICOT” DEPICTION OF THE STUDY
- Patients having HRCT thorax (CT index 9 and more) highly suggestive of covid-19 infection.
- Assessment of cardiac function by 2D echocardiography
- Nil
- Outcome cardiac abnormalities, Duration of Hospital stay discharge or death.
- Duration of study will be 6 months or till the sample size is achieved.

3. MATERIALS AND METHODS

3.1 Material
- The study will be done in Acharya Vinoba Bhave Rural Hospital (AVBRH), Sawangi (Meghe), a 1525 inpatient capacity, fully equipped teaching hospital attached to Jawaharlal Nehru Medical College, Wardha, Maharashtra.

3.2 Duration
- Study duration will be 6 months or till the sample size is achieved.

3.3 Study Design
- Prospective observational study

3.4 Inclusion Criteria
- Patients with HRCT thorax (CT index 9 and more) highly suggestive of covid-19 infection, with or without positive RTPCR/RAT

3.5 Exclusion Criteria
- Patients presenting with heart failure or history of heart failure
- Patients with low CT Index (< 9)
3.6 Sample Size

As prevalence of cardiac manifestations were present in 65% (reference), taking 95% confidence interval, 10 power of the study, and 5% margin of error, the sample size came to be around 78.

3.7 Data Collection

Prospectively, we will be studying 78 hospitalised adult patients (≥18 years of age) with HRCT thorax highly suggestive of COVID-19 (CT index 9 and more) with or without RTPCR or RAT positive.

We will record their socio-demographic data, comorbid conditions. Their physical examination will be done on admission. HRCT thorax and laboratory investigations (including D-dimer, CRP, and Serum Ferritin) will be recorded. Risk-stratification will be done according to their COVID-19-NEWS2 score [8,9]. All patients will be undergoing comprehensive detailed transthoracic 2D echocardiography on admission or within 24 hours as per our protocol.

Clinical cardiac manifestations like pulse, blood pressure, signs of heart failure, ECG for arrhythmias will be noted daily during their hospital stay. Clinical outcome i.e. deterioration and/or improvement will be evaluated using COVID-19 WHO Ordinal scale.

In case of discharge or death, day of discharge and day of death will be noted respectively and duration of hospital stay will be calculated. Evaluated subtle echocardiographic abnormalities of COVID-19 patients will be compared with the reference values published previously [10,11,12].

3.8 Echocardiography

Experienced cardiologist in echocardiographic recording and interpretation will be doing 2D ECHO with the equipment - Philips HD11XE, 2-4 MHZ. Linear probe will be used for ECHO.

3.8.1 Left ventricular assessment

4 chamber view of heart is obtained; Left ventricle is visualized.2 screen view of heart is selected. Left ventricle in diastole is noted and image selected. Now, in the second screen left ventricle in systole is selected and image is captured. Now by selecting Simpson's formula, LV EDV and LV ESV are calculated by tracing the LV inner borders in diastole and systole.

Left ventricle Ejection Fraction is calculated by formula:

\[ EF = \frac{(LV\ EDV - LV\ ESV)}{LV\ EDV} \times 100\]

Left ventricular (LV) mass, volumes, diameters and left ventricular ejection fraction will be determined [11]. The velocities of peak, early filling (E wave) and late diastolic filling (A wave), E/A ratio and early filling velocity deceleration period will be included in Mitral inflow measurements. Mitral septal and lateral annular velocities (e') of early diastole will be calculated, in the apical 4-chamber view [11]. Volume of left atrium will measured with the biplane area to length method when the systole ends. From the LV outflow tract, stroke volume will determined, will be helpful in measurement of cardiac index and output.

3.8.2 Right ventricular assessment

In 4-chamber apical views, the whole right ventricle (RV) is being seen, so at the end of systole and diastole RV areas and length of tricuspid annulus will be measured. RV function will be assessed by tricuspid annular plane systolic excursion, systolic tricuspid lateral annular velocity (RV S') will be measured in the 4-chamber apical view. Also fractional area change and myocardial output index (Tei index) is calculated in addition for qualitative grading. For the right-sided hemodynamic evaluation, the velocity of acceleration time of pulmonary flow (PAT) is calculated for determining pulmonary vascular resistance.

3.9 HRCT Thorax

High Resolution Computed Tomography (HRCT) will be done by SOMATOM SCOPE POWER, G-XL-81609 equipment. It can detect ground glass opacities (GGO) more easily in the early stage [13]. The chest CT is very easy to do. Reports will be available faster than RTPCR reports. It enables early and quick diagnosis of initial pneumonia in COVID-19 [14]. The sensitivity of RTPCR was inferior to that of CT thorax (71% vs. 98%, respectively), reported in some studies. Low viral load, inappropriate sample collection, different kits with variation in diagnosis rate and minimally developed technology for the nucleic acid detection are most commonly associated with the low effectiveness of measurement of viral nucleic acid through RTPCR [15].
3.9.1 CT severity Index [16]:

Chart 1. A CT score from 0 to 5 will be awarded to each lobe depending on the involved lobe (in %):

<table>
<thead>
<tr>
<th>Score</th>
<th>Involvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0% involved</td>
</tr>
<tr>
<td>1</td>
<td>&lt; 5% involved</td>
</tr>
<tr>
<td>2</td>
<td>5% to 25% involved</td>
</tr>
<tr>
<td>3</td>
<td>26% to 49% involved</td>
</tr>
<tr>
<td>4</td>
<td>50% to 75% involved</td>
</tr>
<tr>
<td>5</td>
<td>&gt; 75% involved</td>
</tr>
</tbody>
</table>

Addition of the points from each lobe will be our total CT index and it's between 0 to 25 points. The sensitivity is 80.0% and specificity is 82.8%, if we consider the CT cut-off value of 7 to identify severe cases of COVID-19.

3.9.2 COVID-19 news2 score

It determines the illness severity of a patient and prompts need of intervention of critical care for the patients. It is a simple scoring system which includes physiological measurements. Physiological parameters include level of consciousness, temperature, pulse rate, respiration rate, oxygen saturation and systolic blood pressure.

3.10 Statistical Analysis

Null hypothesis for our research is that there are no significant cardiac manifestations of COVID-19. Research shows that cardiovascular complications and manifestations are prevalent in COVID 19X (Alternate hypothesis) [3,4,5,6] STATA Version 14 will be used for analysis. The characteristics of study participants like age, gender, NEWS 2 score and WHO score will be described using frequencies, means, and standard deviations (SD). The Student T Test will be used to compare the means of normally distributed data. Cox-regression methods will be used to evaluate independent risk factors for its outcome like mortality and duration of hospital stay. Categorical variables will be used for Two-tailed Fisher's exact test or chi-squared tests. P-value of <0.05 for the primary endpoint will be considered statistically significant.

78 hospitalised adult patients (≥18 years of age) with HRCT thorax highly suggestive of COVID-19 (CT index 9 and more)

socio-demographic data, comorbid conditions are recorded
laboratory investigations like D-dimer, CRP, Serum ferritin are recorded
covid-19 NEWS2 score is calculated for risk stratification

Comprehensive Detailed Transthoracic 2D echocardiography done on admission or within 24 hours of admission
Left and right ventricular assessment done and important parameters noted

Echocardiological correlation with outcome in the form of duration of hospital stay, improvement and/or deterioration according to COVID-19 WHO ordinal scale will be done

Picture 2. Study morphology
Chart 2. COVID-19 WHO Ordinal Scale

<table>
<thead>
<tr>
<th></th>
<th>Ordinal Scale</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Patients moving with normal activities</td>
</tr>
<tr>
<td>2</td>
<td>Patients moving with limited activities, home O2 requirement, or both</td>
</tr>
<tr>
<td>3</td>
<td>Hospitalized, no O2 therapy #not requiring medical care</td>
</tr>
<tr>
<td>4</td>
<td>Hospitalized, no O2 therapy requiring medical care ongoing</td>
</tr>
<tr>
<td>5</td>
<td>Patients in hospital with any supplemental O2</td>
</tr>
<tr>
<td>6</td>
<td>Patients in hospital either on NIV (Mechanical ventilation with mask) or HFNC (High Flow Nasal Cannula)</td>
</tr>
<tr>
<td>7</td>
<td>Hospitalized, IMV (Mechanical ventilation with endotracheal tube) or ECMO (Extra Corporeal Membrane Oxygenation)</td>
</tr>
<tr>
<td>8</td>
<td>Patient succumbed</td>
</tr>
</tbody>
</table>

4. RESULTS AND DISCUSSION

Many studies reflect on effects of COVID-19 on various systems [17-21]. With our best knowledge, our study will be the systematic as well as first Echocardiographic study of patients of COVID-19 infection in India. We will be discussing the most commonly found abnormality in Echocardiography study in patients of COVID-19. We expect nearly 33% of patients may be having normal 2D ECHO. In accordance with the previous publications, the most common expected echocardiographic abnormality may be RV dilatation with or without dysfunction. We will be discussing risk factors associated with Right ventricular dysfunction. Conditions like pulmonary embolism, pulmonary vasoconstriction leading to hypoxia, loss of lung volume, pneumonia, excess of positive end-expiratory pressure, carbon dioxide retention or a combination of any are the factors increasing pulmonary vascular resistance patients who were hospitalised and may be acutely precipitating RV dysfunction [22,23]. Patients who are older with comorbidities along with worse lung disease (CT Index >9), hypoxia, high filling pressure of left ventrical and raised biomarkers like CRP, D-dimer and troponin-I may cause increase vascular resistance in pulmonary circulation of patients with infection of COVID-19. Hence, we propose multiple factor causes like raised pulmonary vascular resistance, high left atrial pressure and parenchymal lung disease may manifest as a cardiac injury [24-26].

5. CONCLUSIONS AND CLINICAL IMPLICATIONS

Our study will give the evidence that heart may be involved in COVID-19 even if no structural heart disease is there. We will be studying the cardiac abnormality in the COVID-19 patients. An echocardiogram can be useful in identifying aetiology of cardiac injury and possibly targeted treatment. Follow up for long term is required among post-COVID patients to study the delayed cardiac dysfunction or complications of COVID-19.

6. STUDY LIMITATIONS

As the small number of patients has been studied, outcome analysis interpretation should be considered cautiously. Patients having symptoms of heart failure or history of heart failure has been excluded from study. Patients with low CT Index (< 9) also been excluded.

CONSENT

As per international standard or university standard, patients' written consent will be collected and preserved by the author(s).

ETHICAL APPROVAL

As per international standard or university standard written ethical approval will be collected and preserved by the author(s).

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES


